S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

$12.00
+0.37 (+3.18%)
(As of 10:57 AM ET)
Today's Range
$11.28
$12.01
50-Day Range
$10.53
$14.01
52-Week Range
$5.87
$14.74
Volume
9,900 shs
Average Volume
77,316 shs
Market Capitalization
$216.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

INmune Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.3% Upside
$16.00 Price Target
Short Interest
Bearish
12.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of INmune Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.83 out of 5 stars

Medical Sector

860th out of 939 stocks

Biological Products, Except Diagnostic Industry

146th out of 155 stocks

INMB stock logo

About INmune Bio Stock (NASDAQ:INMB)

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Stock Price History

INMB Stock News Headlines

INmune Bio (NASDAQ:INMB) Stock Price Down 4%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
INMB Jun 2024 25.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
INMB Mar 2024 20.000 call
INMB Mar 2024 12.500 put
INMB Feb 2024 15.000 put
INmune Bio Inc (INMB)
INmune Bio: FDA Removes Clinical Hold For Alzheimer's Disease Program
See More Headlines
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+37.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,300,000.00
Net Margins
-12,246.88%
Pretax Margin
-12,246.88%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
$3.35 per share

Miscellaneous

Free Float
11,516,000
Market Cap
$209.57 million
Optionable
Optionable
Beta
1.99
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

INMB Stock Analysis - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INMB shares.
View INMB analyst ratings
or view top-rated stocks.

What is INmune Bio's stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for INmune Bio's stock. Their INMB share price targets range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for INMB
or view top-rated stocks among Wall Street analysts.

How have INMB shares performed in 2024?

INmune Bio's stock was trading at $11.26 at the beginning of the year. Since then, INMB shares have increased by 6.6% and is now trading at $12.00.
View the best growth stocks for 2024 here
.

When is INmune Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our INMB earnings forecast
.

How can I listen to INmune Bio's earnings call?

INmune Bio will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13744427".

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.12. The firm earned $0.01 million during the quarter. INmune Bio had a negative net margin of 12,246.88% and a negative trailing twelve-month return on equity of 52.26%. During the same period in the prior year, the firm earned ($0.36) earnings per share.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Janney Montgomery Scott LLC (0.91%), Royal Bank of Canada (0.32%), UBS Group AG (0.24%) and Fermata Advisors LLC (0.16%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder.
View institutional ownership trends
.

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INMB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners